賴 基 銘 副研究員 / 主治醫師 / 醫務合作辦公室主任

賴基銘 簡歷

上一篇 / 下一篇  2007-09-14 18:03:50

賴 基 銘 副研究員 / 主治醫師 / 醫務合作辦公室主任
Gi-Ming Lai, M.D.
Associate Investigator and Attending Physician
National Institute of Cancer Research


Education

  • M.D., College of Medicine, National Taiwan University, Taiwan (1978)

 

2.  Professional Experiences

  • Associate Investigator and Attending Physician, National Institute of Cancer Research, National Health Research Institutes, Taiwan (2004-presnet)

  • Director, Department of Administration, National Health Research Institutes, Taiwan (2004-presnet)

  • Chief Executive Officer, Formosa Cancer Foundation (1997-present)

  • Associate Professor of Chinese Medical Science, China Medical University (1995-present)

  •  Director, Taiwan Cooperative Oncology Group, National Health Research Institutes, Taiwan (1997-2002)

  • Senior staff, Cancer Collaborative Ward, National Taiwan University Hospital/ National Health Research Institutes, Taiwan (1997-2002)

  • General Secretary, the Chinese Oncology Society

  • Associate Professor of Medicine, Chang Gung Medical College, Taiwan (1990-1996)

  • Co-Director, Preparing Office for Chang Gung Memorial Tumor Institute, Taiwan (1989-1996)

  • Visiting Associate, Experimental Therapeutics Section, Medicine Branch, COP, DCT, NCI, NIH, USA (1987-1989)

  • Medical Staff, Department of Internal Medicine, Division of Hematology-Oncology, CGMH (1982-1996)

 

3.  Research Interests

In addition to the expertise in clinical trial, Dr. Lai's research interest is to looking for more efficacious cancer therapy by combining drugs or seeking active ingredients of natural products from which are regarding as Complementary and Alternative Medicine (CAM). Dr. Lai evaluates those candidates by examining their molecular targeting effects in the aspects of differentiation induction, cell cycle regulation, signal transduction inhibition, reversal of drug resistance, and chemoprevention.

 

4. RESEARCH ACTIVITIES & ACCOMPLISHMENTS

In searching for more efficacious cancer therapy, Dr. Lai had found that combining mevalonate pathway inhibitor “lovastatin” with peroxisome proliferator-activated receptor γ (PPAR γ) agonist “troglitazone” or with alcoholic extract of Antrodia camphorata could exert synergistic anticancer effects in various types of cancer cells. The U.S. patent applications for these two findings are pending. (Patent Application Publication, Pub. No.: US 2005/0209292 A1). His study also demonstrated the mechanisms responsible for anticancer effects of the human urinary extract “CDA-2” were majorly related to molecular targeting, such as induction of differentiation and apoptosis, cell cycle regulation, signal transduction inhibition, antiangiogenesis, and reversal of chemo-resistance, and radio-resistance. CDA-2 had been approved as a first class new anti-cancer drug by the SFDA of mainland China in 2004 through the effort of both side of Taiwan Strait.

5. PATENTS

Gi-Ming Lai, et al. “Cancer Therapy” US 2005/0209292A1

 

6. Publications

 [ Publications ]

  1. Chen CN, Huang HH, Wu CL, Lin CP, Hsu JT, Hsieh HP, Chuang SE, Lai GM. Isocostunolide, a sesquiterpene lactone, induces mitochondrial membrane depolarization and caspase-dependent apoptosis in human melanoma cells. Cancer Lett. 2006. [Epub ahead of print]
  2. Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY, Chuang SE. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer. 118(3):773-9, 2006.
  3. Yao CJ, Lai GM, Chan CF, Yang YY, Liu FC, Chuang SE. Differentiation of pheochromocytoma PC12 cells induced by human urine extract and the involvement of the extracellular signal-regulated kinase signaling pathway. J Altern Complement Med. 11(5):903-8, 2005.
  4. Yan MD, Hong CC, Lai GM, Cheng AL, Lin YW, Chuang SE. Identification and characterization of a novel gene Saf transcribed from the opposite strand of Fas. Hum Mol Genet. 14(11):1465-74, 2005.
  5. Chuang SE, Yeh PY, Lu YS, Lai GM, Liao CM, Gao M, Cheng AL. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol. 63(9):1709-1716, 2002.
  6. Putti TC, To KF, Hsu HC, Chan ATC, Lai GM, Tse G, Lee YS, Whang-Peng J, Millward M, Lin L and Lee CS. Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. Histopathology, 41:144-151, 2002.
  7. Wu MF, Han CH, Liu CC and Lai GM, et al. Establishment of animal models for the evaluation of differentiation inducing agents. Bullitin Chin. Cancer, 11(3):163-165, 2002.
  8. Wu MF, Han CH, Liu CC and Lai GM. Antitumor effect of CDA-2 on xenograft human hepatoma in SCID mice. J. Chin. Soc. Vet. Sci., 26(4): 317-321, 2000.
  9. Chuang SE, Kuo ML, Hsu CH, Chen CR, Lin JK, Lai GM, Hsieh CY, and Cheng AL. Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. Carcinogenesis. 21(2):331-335, 2000.

  [ Manuscripts submitted or in preparation ]

  1. Ch'ang HJ, Chuang SE, Hsieh CW, Liu FC, Chen YF, Lai GM. CDA-2 potentiate Taxol    cytotoxicity in Doxorubicin resistant MCF7 cells.
  2. Ch'ang HJ, Chuang SE, Hsieh CW, Liu FC, Chen YF, Lai GM. Down regulation of erbB2 protein expression by CDA-2 correlates with enhancement of Taxol cytotoxicity in Doxorubicin resistant MCF7 cells.
  3. Lai GM, Hsieh CW, Liu FC, Chen YF, Chang HJ and Chuang SE. Induction of differentiation and apoptosis in human leukemia (HL-60) cells by human urine extracts (CDA-2) and augmented by all-trans retinoic acid.
  4. Chan CF, Chuang SE, Chen CH and Lai GM. CDA-2 augment 1,25-dihydroxyvitamin D3 induced growth arrest and differentiation in HL-60 cells
  5. Hsieh CW, Lai GM, Chang HJ, Liu FC, Chen YF, Hong CC, Yao CJ and Chuang SE. Induction of differentiation but not apoptosis by human urine extracts (CDA-2) in arsenic trioxide treated NB4 cells.
  6. Hsieh CW, Lai GM, Chang HJ, Liu FC, Chen YF, Hong CC, Yao CJ and Chuang SE.  MEK / MAPK pathway involved in CDA-2 induced growth arrest and differentiation in HL-60 cells.
  7. Lai GM, Chan CF, Yao CJ, Liu FC, and Chuang SE. Potentiation of CDA-2 induced differentiation and apoptosis by antioxidant and nutraceuticals.
  8. Chan CF, Chuang SE, Yao CJ, Chen CH and Lai GM.  Mitochondrial dysfunction and cytochrome C release are responsible for CDA-2 induced apoptosis in H9 lymphoma cells.
  9. Yao CJ, Lai GM, Chan CF, Yang YY and Chuang SE.  Modulation of mitochondrial and NF-kB function in CDA-2 induced apoptosis in human hepatocellular carcinoma cells.
  10. Yao CJ, Lai GM, Chan CF, Yang YY and Chuang SE.  CDA-2 activates MAP kinase and protects PC12 cells against serum deprivation induced apoptosis.
  11. Lai GM, Wu  MF, Lai YC, Chang GH, Zhang Y and Feng FY. The Efficacy of CDA-2 in the treatment of recurrent and metastatic brain tumor.
  12. Lai GM. CDA-2 as an alternative molecular targeting anti-cancer agent in the treatment of gastrointestinal stromal tumor (GIST) -- one case report.
  13. Lai GM, Wu MF, Yao CJ, Chan CF, Chen CH, Gao YT and Feng FY.  CDA-2 as a novel molecular targeting anti-cancer agent in the treatment of hepatocellular carcinoma.
  14. Lai GM, Wu MF, Chan CF, Chen CH, Wang HC and Feng FY. CDA-2 as a novel differentiation induction agent in the treatment of renal cell carcinoma.
  15. Wu MF, Han CH, Liu CC and Lai GM. CDA-2 prevent lung metastasis of B16-F10 melanoma cells in mice model correlate with down regulation of erbB2 and COX-2 expression.
  16. Wu MF, Han CH, Liu CC and Lai GM. Antiangiogenesis properties of shark cartilage extract (Neovastat) responsible for antitumorigenesis of hepatoma xenograft on SCID mice and prevent lung metastasis of B16F10 melanoma cells.

 [ Conference Abstracts ]

  1. Chen CH, Chan CF, Liu CH, Lai JD, Yao CJ, Chuang SE, Lai GM, Mitochondrial Dysfunction And Cytochrome C Release Are Possibly Responsible For CDA-Ⅱ Induced Apoptosis In H9 Lymphoma Cells. The 10th SCBA International Symposium, 2003.
  2. Yao CJ, Yang YY, Lai GM, Chan CF, Chuang SE, Human Urine Extract CDA-Ⅱ Antagonizes The Amyloid β Peptide Altered Cellular MTT Reduction And Intracellular Vesicle Trafficking. The 10th SCBA International Symposium, 2003.
  3. Yao CJ, Wang CK, Yang YY, Lai GM, Chan CF, Chuang SE, Human Urine Extract  CDA-Ⅱ Induced Neuronal Differentiation Of  Pheochromocytoma PC12 Cells And The Involvement Of MAP Kinases Signaling Pathway. The 10th SCBA International Symposium, 2003.
  4. Chan CF, Chen YF, Liu F, Wang CK, Chen CH, Yao CJ, Chuang SE, Lai GM, Arsenic Trioxide-Induced Apoptosis Was Switched To Differentiation By CDA-Ⅱ In NB4 Cells. The 10th SCBA International Symposium, 2003.
  5. Yao CJ, Lai GM, Yang YY, Chan JF, Lai JD, Chuang SE, Antiapoptotic and cytotoxic properties of human urine extract CDA-Ⅱ in PC12 cells. The 7th Taiwan Joint Cancer Conference, 2002.
  6. Chan CF, Chuang SE, Chen CH, Liu FC, Liu CH, Lai GM, CDA-Ⅱ and Enhancement of Growth Arrest and Differentiation of HL-60 Cells Initiated by 1,25-Dihydroxyvitamin D3. The 7th Taiwan Joint Cancer Conference, 2002.
  7. Chen CH, Chan CF, Chuang SE, Liu FC, Liu CH, Lai GM, CDA-Ⅱ and Genes Involved in Regulation of Cell Differentiation in HL-60. The 7th Taiwan Joint Cancer Conference, 2002.

TAG:

 

評分:0

我來說兩句

顯示全部

:loveliness: :handshake :victory: :funk: :time: :kiss: :call: :hug: :lol :'( :Q :L ;P :$ :P :o :@ :D :( :)

Open Toolbar